Differential transcriptional responses to interferon-α and interferon-γ in primary human hepatocytes

Journal of Interferon and Cytokine Research

Volumn 30, Issue 5, 2010, Pages 311-320

  He, Xiao Song ^a,b   Nanda, Santosh ^c   Ji, Xuhuai ^a,b   Calderon Rodriguez, Gloria M ^c   Greenberg, Harry B ^a,b   Liang, T Jake ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; GAMMA1B INTERFERON; ALPHA INTERFERON; GAMMA INTERFERON;

ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSCRIPTION; HEPATITIS VIRUS; HUMAN; HUMAN CELL; LIVER CELL; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; CELL CULTURE; COMPARATIVE STUDY; CULTURE TECHNIQUE; DNA MICROARRAY; DRUG EFFECTS; GENE EXPRESSION PROFILING; HEPATITIS B; HEPATITIS C; IMMUNOLOGY; METABOLISM; PATHOLOGY;

HEPATITIS C VIRUS;

CELL CULTURE TECHNIQUES; CELLS, CULTURED; GENE EXPRESSION PROFILING; HEPATITIS B; HEPATITIS C; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 77952571243     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2009.0082     Document Type: Article

References (40)

1. Chang KS, Cai Z, Zhang C, Sen GC, Williams BR, Luo G. 2006. Replication of hepatitis C virus (HCV) RNA in mouse embryonic fi broblasts: protein kinase R (PKR)-dependent and PKRindependent mechanisms for controlling HCV RNA replication and mediating interferon activities. J Virol 80(15):7364-7374.
2. Der SD, Zhou A, Williams BR, Silverman RH. 1998. Identifi cation of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 95(26):15623-15628.
3. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, Schweigler LM, Theodore D, Zacks SL, Liang TJ, Fried MW. 2007. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 46(5):1548-1563.
4. Frese M, Schwarzle V, Barth K, Krieger N, Lohmann V, Mihm S, Haller O, Bartenschlager R. 2002. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35(3):694-703.
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347(13):975-982.
6. Gautier G, Humbert M, Deauvieau F, Scuiller M, Hiscott J, Bates EE, Trinchieri G, Caux C, Garrone P. 2005. A type I interferon autocrine-paracrine loop is involved in Toll-like receptorinduced interleukin-12p70 secretion by dendritic cells. J Exp Med 201(9):1435-1446.
7. He XS, Ji X, Hale MB, Cheung R, Ahmed A, Guo Y, Nolan GP, Pfeffer LM, Wright TL, Risch N, Tibshirani R, Greenberg HB. 2006. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modifi ed by race. Hepatology 44(2):352-359.
8. Helbig KJ, Lau DT, Semendric L, Harley HA, Beard MR. 2005. Analysis of ISG expression in chronic hepatitis C identifi es viperin as a potential antiviral effector. Hepatology 42(3):702-710.
9. Huang Y, Feld JJ, Sapp RK, Nanda S, Lin JH, Blatt LM, Fried MW, Murthy K, Liang TJ. 2007. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 132(2):733-744.
10. Ji X, Cheung R, Cooper S, Li Q, Greenberg HB, He XS. 2003. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology 37(3):610-621.
11. Jiang D, Guo H, Xu C, Chang J, Gu B, Wang L, Block TM, Guo JT. 2008. Identifi cation of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol 82(4):1665-1678.
12. Kakumu S, Ishikawa T, Mizokami M, Orido E, Yoshioka K, Wakita T, Yamamoto M. 1991. Treatment with human gamma interferon of chronic hepatitis B: comparative study with alpha interferon. J Med Virol 35(1):32-37.
13. Kato T, Matsumura T, Heller T, Saito S, Sapp RK, Murthy K, Wakita T, Liang TJ. 2007. Production of infectious hepatitis C virus of various genotypes in cell cultures. J Virol 81(9):4405-4411.
14. Kostrubsky VE, Ramachandran V, Venkataramanan R, Dorko K, Esplen JE, Zhang S, Sinclair JF, Wrighton SA, Strom SC. 1999. The use of human hepatocyte cultures to study the induction of cytochrome P-450. Drug Metab Dispos 27(8):887-894.
15. Lai L, Hui CK, Leung N, Lau GK. 2006. Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B. Int J Nanomedicine 1(3):255-262.
16. Lanford RE, Guerra B, Lee H, Averett DR, Pfeiffer B, Chavez D, Notvall L, Bigger C. 2003. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol 77(2):1092-1104.
17. Lanford RE, Guerra B, Lee H, Chavez D, Brasky KM, Bigger CB. 2006. Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology 43(5):961-972.
18. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. 2005. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352(26):2682-2695.
19. Lau JY, Lai CL, Wu PC, Chung HT, Lok AS, Lin HJ. 1991. A randomised controlled trial of recombinant interferon-gamma in Chinese patients with chronic hepatitis B virus infection. J Med Virol 34(3):184-187.
20. Leung N. 2002. Treatment of chronic hepatitis B: case selection and duration of therapy. J Gastroenterol Hepatol 17(4):409-414.
21. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286):958-965. (Pubitemid 32913521)
22. Marcellin P, Loriot MA, Boyer N, Martinot-Peignoux M, Degott C, Degos F, Brandely M, Lenfant B, Benhamou JP. 1990. Recombinant human gamma-interferon in patients with chronic active hepatitis B: pharmacokinetics, tolerance and biological effects. Hepatology 12(1):155-158.
23. Muller M, Briscoe J, Laxton C, Guschin D, Ziemiecki A, Silvennoinen O, Harpur AG, Barbieri G, Witthuhn BA, Schindler C. 1993. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature 366(6451):129-135.
24. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. 1998. Hepatitis C viral dynamics in vivo and the antiviral effi cacy of interferon-alpha therapy. Science 282(5386):103-107.
25. Pan J, Zhang M, Wang J, Wang Q, Xia D, Sun W, Zhang L, Yu H, Liu Y, Cao X. 2004. Interferon-gamma is an autocrine mediator for dendritic cell maturation. Immunol Lett 94(1-2):141-151.
26. Persico M, Capasso M, Persico E, Svelto M, Russo R, Spano D, Croce L, La Mura V, Moschella F, Masutti F, Torella R, Tiribelli C, Iolascon A. 2007. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology 46(4):1009-1015.
27. Platanias LC. 2005. Mechanisms of type-I- and type-II-interferonmediated signalling. Nat Rev Immunol 5(5):375-386.
28. Runge D, Kohler C, Kostrubsky VE, Jager D, Lehmann T, Runge DM, May U, Stolz DB, Strom SC, Fleig WE, Michalopoulos GK. 2000. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Biochem Biophys Res Commun 273(1):333-341.
29. Samuel CE. 1991. Antiviral actions of interferon. Interferonregulated cellular proteins and their surprisingly selective antiviral activities. Virology 183(1):1-11.
30. Samuel CE. 2001. Antiviral actions of interferons. Clin Microbiol Rev 14(4):778-809, table of contents.
31. Sanda C, Weitzel P, Tsukahara T, Schaley J, Edenberg HJ, Stephens MA, McClintick JN, Blatt LM, Li L, Brodsky L, Taylor MW. 2006. Differential gene induction by type I and type II interferons and their combination. J Interferon Cytokine Res 26(7):462-472.
32. Sen GC. 2001. Viruses and interferons. Annu Rev Microbiol 55:255-281.
33. Soza A, Heller T, Ghany M, Lutchman G, Jake Liang T, Germain J, Hsu HH, Park Y, Hoofnagle JH. 2005. Pilot study of interferon gamma for chronic hepatitis C. J Hepatol 43(1):67-71.
34. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. 1998. How cells respond to interferons. Annu Rev Biochem 67:227-264.
35. Strom SC, Pisarov LA, Dorko K, Thompson MT, Schuetz JD, Schuetz EG. 1996. Use of human hepatocytes to study P450 gene induction. Meth Enzymol 272:388-401.
36. Taylor DR, Puig M, Darnell ME, Mihalik K, Feinstone SM. 2005. New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1. J Virol 79(10):6291-6298.
37. Tusher VG, Tibshirani R, Chu G. 2001. Signifi cance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98(9):5116-5121.
38. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, Powell EE. 2006. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 55(4):529-535.
39. Wang C, Pfl ugheber J, Sumpter R Jr, Sodora DL, Hui D, Sen GC, Gale M Jr. 2003. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol 77(7):3898-3912.
40. Watling D, Guschin D, Muller M, Silvennoinen O, Witthuhn BA, Quelle FW, Rogers NC, Schindler C, Stark GR, Ihle JN. 1993. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature 366(6451):166-170.